Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald increased their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. HC Wainwright started coverage on Vanda Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $18.00 price target on the stock.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA opened at $4.65 on Friday. The company has a market cap of $271.05 million, a price-to-earnings ratio of -24.47 and a beta of 0.77. The stock’s fifty day moving average price is $4.86 and its 200 day moving average price is $5.23. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The firm had revenue of $50.47 million during the quarter. Research analysts expect that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Sei Investments Co. lifted its position in shares of Vanda Pharmaceuticals by 39.6% during the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $1,158,000. Acadian Asset Management LLC raised its position in shares of Vanda Pharmaceuticals by 4.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after purchasing an additional 107,203 shares during the last quarter. Monaco Asset Management SAM acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $1,090,000. Finally, Empowered Funds LLC lifted its stake in Vanda Pharmaceuticals by 8.2% in the 1st quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock valued at $827,000 after buying an additional 15,215 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.